Short Term Magnesium Preventation In Menstrually Related Migraine (MRM)

Studying effectiveness of Short Term oral Magnesium supplement Prophylaxis In Menstrually Related Migraine (MRM) in women in reproductive ages : A Randomized Controlled Trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190415043284N1

Enrollment

Registered

2019-08-15

Start date

2019-01-21

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Menstrually Related Migraine (MRM).

Interventions

Intervention group: each patient during 3 continuous menstrual cycles, taking one and half (375 milligrams) of 250 miligrames magnesium oxide pills from Jalinous Pharmaceutical company daily and reco

Eligibility

Sex/Gender

Female

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: patients affected by menstrually related migraine according to 3rd edition of The International Classification of Headache Disorders regular mense

Exclusion criteria

Exclusion criteria: chronic diarrhea renal failure nephrolithiasis myasthenia gravis patients anti hypertensive drug usage particularly calcium channel blocker users diabetic patients who has insulin resistance state pregnancy or planned pregnancy; ; menstrual migraine [14] breast feeding women non migraine headache psychiatric illness according to DSM5 criteria chronic systemic illness dependence or abuse of drugs intake of antidepressants, neuroleptics, minor or major tranquillizers, drugs used for the treatment of affective disorders (e.g. lithium, carbamazepine), antiepileptics bradrychardia anti coagulant and antiplatelet usage pure menstrually migraine

Design outcomes

Primary

Measure	Time frame
Headache attacks of menstrually related migraine. Timepoint: 4 questionnaires are filled: the first one at the sampling time and 3 others during 3 continuous menstrual cycles which the participant take pills. Method of measurement: questionnaire.	—

Secondary

Measure	Time frame
Headache frequency, intensity, prolongation, amount of analgesic drugs and resulting palliation. Timepoint: 4 questionnaires are filled: the first one at the sampling time and 3 others during 3 continuous menstrual cycles which the participant take pills. Method of measurement: Each questionnaire contains a calendar with blanks to record: the exact date of menstruation starting date, headache days, headache intensity ( 1 to 10 scale), each headache attack prolongation (hours), number of analgesic pills to pain relief and resulting palliation (describes with excellent, good, intermediate and poor response).	—

Measure

Time frame

Headache frequency, intensity, prolongation, amount of analgesic drugs and resulting palliation. Timepoint: 4 questionnaires are filled: the first one at the sampling time and 3 others during 3 continuous menstrual cycles which the participant take pills. Method of measurement: Each questionnaire contains a calendar with blanks to record: the exact date of menstruation starting date, headache days, headache intensity ( 1 to 10 scale), each headache attack prolongation (hours), number of analgesic pills to pain relief and resulting palliation (describes with excellent, good, intermediate and poor response).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactEhsan Mohammadiani Nejad

Ahvaz University of Medical Sciences

p.yabande@gmail.com+98 61 3374 3001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026